Komori
ASKA Pharmaceutical Holdings (4886) · InitiativeFirst stated

Discontinuation of L-105 Development for Crohn's Disease

First written in FY2023. . Latest entry: FY2023.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Discontinuation of L-105 Development for Crohn's DiseaseA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2023First statedAnnual report

    「なおL-105のクローン病を対象とした開発は中止しました。」

    L-105のクローン病を対象とした開発を中止したことを初めて個別テーマとして記載している。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
ASKA Pharmaceutical Holdings's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.